You are here

International Journal of Immunopathology and Pharmacology


eISSN: 20587384 | ISSN: 03946320 | Current volume: 37 | Current issue: 1 Frequency: Yearly


International Journal of Immunopathology and Pharmacology is a peer-reviewed open access journal that publishes original papers describing research in the fields of immunology, pathology and pharmacology. Please see the Aims and Scope tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).

Indexed in: PubMed, SCIE & Scopus

Published by SAGE since 2016

An expert and prestigious Editorial Board

Publication is subject to payment of an article processing charge (APC).


Submission information

Submit your manuscript today at https://mc.manuscriptcentral.com/iji

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access article processing charge (APC) information

The APC for this journal is currently $2650 USD.

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.

Contact

Please direct any queries to priyanka.gupta@sagepub.in


*The article processing charge (APC) is payable when the manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.

International Journal of Immunopathology and Pharmacology is a peer-reviewed, open access journal publishing original papers describing research in the fields of immunology, pathology and pharmacology. The intention is that the journal should reflect both the experimental and clinical aspects of immunology as well as advances in the understanding of the pathology and pharmacology of the immune system.

Editor
Priyanka Gupta SAGE Publishing, India
Editorial Board
Subhadip Banerjee Jadavpur University, India
Magdalena Beata Skarzynska Institute of Sensory Organs, Poland
Ozge Cemiloglu Ulker Ankara University, Turkey
Allen Cheung Hong Kong Baptist University, Hong Kong
Undurti N. Das Indian Institute of Technology-Hyderabad, India
G Donato University Magna Graecia, Italy
Kempuraj Duraisamy Tufts University School of Medicine, USA
Enrico Garaci University of Rome, Italy
Mario Di Gioacchino University of Chieti-Pescara, Italy
N. Gorbunov Walter Reed Army Institute of Research, USA
R Guabiraba INRA, UMR1282 Infectiologie et Santé Publique, France
Kenneth Honn Wayne State University, USA
Partha K. Chandra Tulane University School of Medicine, United States
S. Leeman Boston University School of Medicine, USA
Clelia Madeddu University of Cagliari, Italy
F. Pandolfi Catholic University Rome, Italy
Kim Rainsford Sheffield Hallam University, UK
Carlo Riccardi University of Perugia, Italy
G. Ricevuti University of Pavia, Italy
Alessandro Rizzo IRCCS Istituto Tumori Giovanni Paolo II, Italy
Soheil Saeedi University of Zurich, Switzerland
Daniel N. Sauder Princeton University Medical Center, USA
Sozzani Silvano University of Brescia, USA
Diego Vergani King's College Hospital, UK
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • ProQuest
  • PubMed: MEDLINE
  • SCOPUS

International Journal of Immunopathology and Pharmacology

Manuscript Submission Guidelines

  1. Open Access
  2. Article processing charge (APC)
  3. What do we publish?
    3.1 Aims & scope
    3.2 Article types
    3.3 Writing your paper
  4. Editorial policies
    4.1 Peer review policy
    4.2 Authorship
    4.3 Acknowledgements
    4.4 Funding
    4.5 Declaration of conflicting interests
    4.6 Research ethics and patient consent
    4.7 Clinical trials
    4.8 Reporting guidelines
    4.9 Research Data
  5. Publishing policies
    5.1 Publication ethics
    5.2 Contributor's publishing agreement
  6. Preparing your manuscript
    6.1 Word processing formats
    6.2 Artwork, figures and other graphics
    6.3 Supplementary material
    6.4 Reference style
    6.5 English language editing services
  7. Submitting your manuscript
    7.1 How to submit your manuscript
    7.2 Title, keywords and abstracts
    7.3 Information required for completing your submission
    7.4 ORCID
    7.5 Information required for completing your submission
    7.6 Permissions
  8. On acceptance and publication
    8.1 Sage Production
    8.2 Online publication
    8.3 Promoting your article
  9. Further information
  10. Appealing the publication decision

This Journal is a member of the Committee on Publication Ethics.

This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/iji to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

Only manuscripts of sufficient quality that meet the aims and scope of International Journal of Immunopathology and Pharmacology will be reviewed.

As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

European Journal of Inflammation may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy.

If your paper is accepted, you must include a link on your preprint to the final version of your paper.

If you have any questions about publishing with Sage, please visit the Sage Journal Solutions Portal

1. Open Access

International Journal of Immunopathology and Pharmacology is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

For general information on open access at Sage please visit the Open Access page or view our Open Access FAQs.

Return to top

2. Article processing charge (APC)

If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.

The APC for this journal is $2650.

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested.  Please see further details here

Return to top

3. What do we publish?

3.1 Aims & scope

Before submitting your manuscript to International Journal of Immunopathology and Pharmacology, please ensure you have read the Aims & Scope.

3.2 Article types

The journal publishes original papers describing research in the fields of immunology, pathology, pharmacology and general experimental and clinical medicine related to inflammation.

Original Research: Abstracts should be a maximum of 250 words and should be structured appropriately. The introduction should not exceed 600 words and the Discussion 1,500 words. There is no word limit on Methods and Results however, the manuscript’s readability may suffer if these sections are excessively long. Authors should therefore consider what data and analyses might be appropriate for supplemental information. There is no limit to the number of references.

Reviews: literature reviews, systematic reviews, market reviews and critical reviews will be accepted for consideration. Reviews must contain no more than 5,000 words. There are no limits to figures or references, but authors are advised that the Editorial Board will not accept poorly focused reviews.

Letter to the Editor: Short reports allow authors to publish the results from a small number of experiments, provided that the results are novel or of high importance. Findings should be clear and of interest to most readers. Intended as a short format, these articles should be a maximum of 2,000 words and 2 figures and 10 references.

Case reports: A case report may include a single case study or case series. They should be based on an interesting observation, or an unique case. Case reports should be no more than 1,000 words and include no more than 20 references.

Letters to the Editor: Correspondence to the Editor unrelated to a specific article should not exceed 500 words or have more than 3 references. Correspondence pertaining to a recently published article or to be published concurrently with an article within the journal should not exceed 800 words or have more than 5 references.

Note: Research involving Chinese Traditional Medicine (CTM) or other similar alternative medicines is not within the scope of International Journal of Immunopathology and Pharmacology, and therefore will not be considered for publication. All research submitted to International Journal of Immunopathology and Pharmacology must be evidence-based.

3.3 Writing your paper

The Sage Author Gateway has some general advice and on how to get published, plus links to further resources.

3.3.1 Making your article discoverable

For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online

Return to top

4. Editorial policies

4.1 Peer review policy

The journal’s policy is to have manuscripts reviewed by two expert reviewers. International Journal of Immunopathology and Pharmacology utilizes a single-anonymize peer review process in which the reviewer’s name and information is withheld from the author. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor who then makes the final decision.

The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor / Board member will have no involvement in the decision-making process.

International Journal of Immunopathology and Pharmacology is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for International Journal of Immunopathology and Pharmacology can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.

4.2 Authorship

Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

The list of authors should include all those who can legitimately claim authorship. This is all those who:

  1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
  2. Drafted the article or revised it critically for important intellectual content,
  3. Approved the version to be published,
  4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.

4.3 Acknowledgements

All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

4.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

  • Disclose this type of editorial assistance – including the individual’s name, company and level of input
  • Identify any entities that paid for this assistance
  • Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.

Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

4.3.2 Writing assistance

Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.

It is not necessary to disclose use of language polishing services.

Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

4.4 Funding

International Journal of Immunopathology and Pharmacology requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

4.5 Declaration of conflicting interests

It is the policy of International Journal of Immunopathology and Pharmacology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

For guidance on conflict of interest statements, please see the ICMJE recommendations.

4.6 Research ethics and patient consent

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.

4.6.1 Declarations

**Please note that all manuscripts should be accompanied by a separate document entitled 'Author Declarations Form'.**

Please read the Declarations guidelines for authors (below) carefully before submitting your Author Declarations Form.

This should be submitted under the file designation ‘'Author Declarations Form’ with your manuscript file, and please note that manuscripts which do not include these Declarations will be returned. These declaration statements will be published at the end of every accepted manuscript.

Please download the Author Declarations Form corresponding to your article type below and complete ALL sections. Please delete all text that does NOT apply to your manuscript and provide specific information where applicable and indicated by asterisks (*).

Human research and in vitro studies: Download form here.
Animal research studies: Download form here.
Review and other articles: Download form here.
Studies involving both humans and animals: Download form here.
Case Reports and Case Series: Download form here.

4.7 Clinical trials

International Journal of Immunopathology and Pharmacology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

4.8 Reporting guidelines

The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

4.9 Research Data

The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages.

Subject to appropriate ethical and legal considerations, authors are encouraged to:

  • share your research data in a relevant public data repository
  • include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
  • cite this data in your research

Return to top

5. Publishing policies

5.1 Publication ethics

Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway.

5.1.1 Plagiarism

International Journal of Immunopathology and Pharmacology and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

5.1.2 Prior publication

If material has been previously published, it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the Editor at the address given below.

5.2 Contributor's publishing agreement

Before publication Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement.  International Journal of Immunopathology and Pharmacology publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit Sage's OA licenses page.

Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

Return to top

6. Preparing your manuscript

6.1 Word processing formats

The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

6.2 Artwork, figures and other graphics

For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines.  

Figures supplied in color will appear in color online.

6.3 Supplementary material

This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article.  For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.

6.4 Reference style

International Journal of Immunopathology and Pharmacology adheres to the Sage Vancouver reference style. Please review the guidelines on Sage Vancouver to ensure your manuscript conforms to this reference style.

If you use EndNote to manage references, you can download the Sage Vancouver output file here.

6.5 English language editing services

Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.

Return to top

7. Submitting your manuscript

7.1 How to submit your manuscript

International Journal of Immunopathology and Pharmacology is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/iji to login and submit your article online.

IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

7.2 Title, keywords and abstracts

Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the Sage Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.

7.3 Information required for completing your submission

Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

7.4 ORCID

As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

7.5 Information required for completing your submission

You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed on the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

7.6 Permissions

Please ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Journal Author Gateway.

Return to top

8. On acceptance and publication

If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for Sage Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.

8.1 Sage Production

Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal Sage Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. 

8.2 Online publication

One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

8.3 Promoting your article

Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.

Return to top

9. Further information

Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the International Journal of Immunopathology and Pharmacology editorial office as follows:

Email: Pooja Sharma (pooja.sharma@sagepub.co.uk)

Commercial correspondence including advertising, requests for back numbers and reprints should be sent electronically to Manuela Brun (manuela.brun@sagepub.co.uk) or to the Editor-in-Chief.

Return to top

10. Appealing the publication decision

Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.

If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at publication_ethics@sagepub.com